Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of Gleevec (imatinib
mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing
fewer side effects than standard high dose chemotherapy.